Company Filing History:
Years Active: 2010-2013
Title: Masaru Hamaoki: Innovator in Medical Science
Introduction
Masaru Hamaoki is a distinguished inventor based in Choshi, Japan. He has made significant contributions to the field of medical science, particularly in understanding the effects of macrophages and pulmonary surfactant proteins. With a total of three patents to his name, Hamaoki's work is paving the way for advancements in clinical testing and treatment methodologies.
Latest Patents
Hamaoki's latest patents include a method for determining the degree of negative effects of macrophages on vertebrates. This innovative method allows for the assessment of diacetylpolyamine in samples collected from vertebrates, including humans. It provides a means to monitor the metabolic conditions of macrophages and predict various macrophage-related diseases, such as cancer recurrence, Alzheimer's disease, and autoimmune disorders.
Another notable patent is a method for stabilizing pulmonary surfactant protein. This invention involves creating a stabilized aqueous solution containing pulmonary surfactant protein, which is essential for various clinical applications. The method utilizes calcium ions and oxidizing/reducing substances to ensure the long-term stability of the protein, thereby enhancing its utility in medical assays.
Career Highlights
Masaru Hamaoki is currently associated with Yamasa Corporation, where he continues to innovate and contribute to medical research. His work has garnered attention for its potential impact on clinical practices and patient care.
Collaborations
Hamaoki collaborates with Seiji Tanaka, a fellow researcher, to further explore the applications of his inventions in the medical field. Their combined expertise enhances the development of innovative solutions for health-related challenges.
Conclusion
Masaru Hamaoki's contributions to medical science through his patents demonstrate his commitment to improving healthcare outcomes. His innovative methods for assessing macrophage effects and stabilizing pulmonary surfactant proteins are significant advancements in the field.